KINETIC MODELING OF RASAGILINE MESYLATE FROM NANOSCALE SOLID LIPID PARTICLES
Keywords:
Nanoscale solid lipid particles, Nanoparticle release, Kinetic models, Model dependent methodAbstract
Objective: The present study is aimed to investigate the In-vitro release behavior of the Rasagiline mesylate loaded nanoscale solid lipid particles to provide the quality based controlled release system.
Methods: The Rasagiline mesylate loaded Nanoscale particles prepared using the microemulsion technique with biodegradable and biocompatible lipid (stearic acid), surfactant (polyethylene-polypropylene glycol) and co-surfactant (polyoxyethylene20 sorbitanmonooleate). The prepared nanoscale solid lipid particles, particle size distribution, polydispersity index, zeta potential, entrapment efficiency, drug loading and drug content were characterized. The fabricated particles surface morphology was examined by transmission electron microscope. In-vitro release of Rasagiline mesylate loaded nanoscale solid lipid particles was studied using conical flask method. Release kinetics of Rasagiline mesylate from nanoscale solid lipid particles were studied using mathematical models.
Results: The resulting Rasagiline mesylate loaded nanoscale solid lipid particles were successfully prepared with optimum particle size distribution, polydispersity index, zeta potential, entrapment efficiency, drug loading and drug content. Statistically significant differences were found among the drug release profile from RMSLN-I and RMSLN-II. Applying kinetic mathematical models, the mechanism of Rasagiline mesylate loaded nanoscale solid lipid particles release from the two formulations were found to be followed higuchi model, as the plots showed high linearity, with a correlation coefficient (R2) value of 0.98 or more. The ‘n' value of korsmeyer-Peppas model lies below 0.5 and the mechanism controlling the drug release was Fickian diffusion.
Conclusion: The prepared Rasagiline mesylate loaded nanoscale solid lipid particles controlling the drug delivery through diffusion dominated mechanism.Â
Downloads
References
Susan SD Souza, Patrick P Deluca. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res 2006;23:460-74.
Washington c. Drug release from microdisperse systems: a critical review. Int J Pharm 1990;58:1-12.
James E Polli. In-Vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. AAPS J 2008;10:289-99.
Lachman L, Lieberman H, Kanig J. The Theoryand Practice of Industrial Pharmacy, Lea and Febiger, PA; 1987.
Burgess DJ, Hussain AS, Ingallinera TS, Chen M. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci 2002;4:1-12.
Washington C. Drug release from microdisperse systems: a critical review. Int J Pharm 1990;58:1-12.
Mona MA, Abdel-Mottaleb, Alf Lamprech. Standardized In-Vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I. Drug Dev Ind Pharm 2011;37:178-84.
Viveksarathi K, Kannan K. Effect of the moist-heat sterilization on fabricated nanoscale solid lipid particles containing rasagiline mesylate. Int J Pharm Invest 2015;5:1-5.
Paulo Costa, Jose Manuel Sousa Lobo. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.
Suvakanta Dash, Padala Narasimha Murthy, Lilakanta Nath, Prasanta Chowdhury. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharm Drug Res 2010;67:217-23.
Mohammad Barzegar-Jalali, Khosro Adibkia, Hadi Valizadeh, Mohammad Reza Siahi Shadbad, Ali Nokhodchi, Yadollah Omidi, et al. Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci 2008;11:167-77.
Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group. Lancet 2005;365:947-54.
Youdim MB, Maruyama W, Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor anti-Parkinsonian drug, rasagiline. Drugs Today 2005;41:369-91.
David R, P Guay. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor forparkinson's disease. Am J Geriatr Pharmacother 2006;4:331-46.
Jack J Chen, David M Swope, Khashayar Dashtipour. Comprehensive review of Rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007;29:1825-49.
Viveksarathi K, Kannan K. Multi criteria decision making to select the best method for the preparation of solid lipid nanoparticles of rasagiline mesylate using analytic hierarchy process. J Adv Pharm Technol Res 2014;5:115-21.
Patricia Severino, Samantha C Pinho, Eliana B Souto, Maria HA Santana. Polymorphism, crystallinity and hydrophilic–lipophilic balance of stearic acid and stearic acid–capric/caprylic triglyceride matrices for production of stable nanoparticles. Colloids Surf B 2011;86:125-30.
Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i. v. administration to rats. Pharmacol Res 2000;42:337-43.
Viveksarathi K, Kannan K. Experimental design for the optimization of nanoscale solid lipid particles containing rasagiline mesylate. J Young Pharm 2015;7:1-11.
Viveksarathi K, Kannan K. Compatibility studies of rasagiline mesylate with selected excipients for an effective solid lipid nanoparticles formulation. Int J Pharm Pharm Sci 2015;7:73-80.
Chander Parkash Dora, Shailendra Kumar Singh, Sanjeev Kumar, Ashok Kumar Datusalia, Aakash Deep. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Poloniae Pharm Drug Res 2010;67:283-90.
Viveksarathi K, Rajarajan R, Kannan K, Manavalan R. Dosage form design and evaluation of eperisone hydrochloride matrix film coated extended release tablets. Int J Pharm Pharm Sci 2012;4:575-81.
Barnabas Wilson, Malay Kumar Samanta, Kumaraswamy Santhi, Kokilampal Perumal Sampath Kumar, Nallupillai Paramakrishnan, Bhojraj Suresh. Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008;1200:159-68.
Suvakanta Dash, Padala Narasimha Murthy, Lilakanta Nath, Prasanta Chowdhury. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharm Drug Res 2010;67:217-23.
Ozturk SS, Palsson BO, Donohoe B, Dressman JB. Kinetics of release from enteric-coated tablets. Pharm Res 1988;5:550-65.
Dressman JB, Fleisher D. Mixing-tank model for predicting dissolution rate control or oral absorption. J Pharm Sci 1986;75:109-16.
Dressman JB, Fleisher D, Amidon GL. Physicochemical model for dose-dependent drug absorption. J Pharm Sci 1984;73:1274-9.
Varelas CG, Dixon DG, Steiner C. Zero-order release from biphasic polymer hydrogels. J Controlled Release 1995;34:185-92.
Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations-theoretical considerations and application to nondisintegratingdosage forms. J Pharm Sci 1967;56:1238-42.
Wagner JG. Interpretation of percent dissolved–time plots derived from In vitro testing of conventional tablets and capsules. J Pharm Sci 1969;58:1253-7.
Kitazawa, S, Johno I, Ito Y, Teramura S, Okada J. Effects of hardness on the disintegration time and the dissolution rate of uncoated caffeine tablets. J Pharm Pharmacol 1975;27:765-70.
Kitazawa S, Johno I, Ito Y, Teramura S, Okada J. Interpretation of dissolution rate data from in vivo testing of compressed tablets. J Pharm Pharmacol 1977;29:453-9.
Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid propionate polymers. J Pharm Sci 1963;52:1145-9.
Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:874-5.
Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem Res 1931;23:923-31.
Viveksarathi K, Kannan K. Design and In-Vitro evaluation of gastroretentive floating delivery system of rosiglitazone maleate. J Pharm Sci Res 2013;5:166-70.
Viveksarathi V, Kannan K, Selvamuthu Kumar S, Manavalan R. Formulation Development and in-vitro evaluation of gastroretentive floating tablets of atenolol. J Pharm Sci Res 2011;3:1632-6.
Haibin LI, Xuexhem Duan. Nanoparticles for drug delivery to the central nervous system. Nanoscience 2006;11:207-9.
Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Delivery 2001;47:65-81.
Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem: Cent Nerv Syst Agents 2002;2:241-9.
Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Targeting 2003;10:317-25.
Langer RS, Wise DL. Medical applications of controlled release, applications and evaluation. Eds. Vol. I and II. CRC Press: Boca Raton; 1984.